相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The LIN28/let-7 Pathway in Cancer
Julien Balzeau et al.
FRONTIERS IN GENETICS (2017)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B. London et al.
CANCER (2017)
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Navin R. Pinto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Neuroblastoma Paradigm for Precision Medicine
Meredith S. Irwin et al.
PEDIATRIC CLINICS OF NORTH AMERICA (2015)
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma
Giselle L. Saulnier Sholler et al.
PLOS ONE (2015)
Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma
Ann M. Lozier et al.
ONCOTARGET (2015)
Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems
L. E. Cohen et al.
BONE MARROW TRANSPLANTATION (2014)
Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission
Brian H. Kushner et al.
CLINICAL CANCER RESEARCH (2014)
AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport
Katherine Samal et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma
Dana-Lynn T. Koomoa et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission
Nai-Kong V. Cheung et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of alpha-Difluoromethylornithine in Subjects with Previous History of Skin Cancer
Howard H. Bailey et al.
CANCER PREVENTION RESEARCH (2010)
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.
Alice L. Yu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma
Robert J. Rounbehler et al.
CANCER RESEARCH (2009)
Associations of a Polymorphism in the Ornithine Decarboxylase Gene with Colorectal Cancer Survival
Jason A. Zell et al.
CLINICAL CANCER RESEARCH (2009)
Genetic polymorphism in ornithine decarboxylase and risk of breast cancer
Iain Brown et al.
FAMILIAL CANCER (2009)
New Therapeutic Targets for the Treatment of High-Risk Neuroblastoma
Lars M. Wagner et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
Susan L. Cohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study
Caroline Laverdiere et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Disease control intervals in high-risk neuroblastoma
Victor M. Santana et al.
CANCER (2008)
Ornithine Decarboxylase Inhibition by α-Difluoromethylornithine Activates Opposing Signaling Pathways via Phosphorylation of Both Akt/Protein Kinase B and p27Kip1 in Neuroblastoma
Dana-Lynn T. Koomoa et al.
CANCER RESEARCH (2008)
ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma
Michael D. Hogarty et al.
CANCER RESEARCH (2008)
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial
F Berthold et al.
LANCET ONCOLOGY (2005)
Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk
K Visvanathan et al.
JOURNAL OF UROLOGY (2004)
Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
T Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
